Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 02, 2020 | Director | Initial Statement of Beneficial Ownership of Securities | Form 3 | -- | -- | -- | |
| Nov 02, 2020 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 23,975 | -- | -- | |
| Oct 09, 2020 | Chief Science Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 43,700 | -- | -- | |
| Oct 09, 2020 | Chief Science Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 75,000 | -- | -- | |
| Oct 09, 2020 | Chief Science Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 75,000 | -- | -- | |
| Aug 03, 2020 | Director, Chief Operating Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 10,000 | -- | -- | |
| Jul 09, 2020 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 11,559 | -- | -- | |
| Jul 09, 2020 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 8,850 | -- | -- | |
| Jul 09, 2020 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 17,896 | -- | -- | |
| Jun 01, 2020 | Director | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 5,000 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.